Bio Rad Laboratories Inc (N:BIO)

Business Focus: Medical Equipment, Supplies & Distribution

Mar 20, 2024 08:30 am ET
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024.
Feb 22, 2024 04:30 pm ET
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time).
Feb 15, 2024 04:15 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023.
Jan 24, 2024 05:00 pm ET
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jan 02, 2024 04:15 pm ET
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, President and CEO, and Andrew Last, Executive Vice President and COO, will host one-on-one meetings with investors during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, January 8 - 11, 2024.
Oct 26, 2023 04:15 pm ET
Bio-Rad Reports Third-Quarter 2023 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.
Oct 05, 2023 08:30 am ET
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Aug 28, 2023 04:15 pm ET
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).
Aug 03, 2023 04:15 pm ET
Bio-Rad Reports Second-Quarter 2023 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.
Jul 26, 2023 04:15 pm ET
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
Jul 20, 2023 04:30 pm ET
Bio-Rad Announces New Share Repurchase Program
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.
Jul 10, 2023 04:30 pm ET
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jul 10, 2023 09:00 am ET
Bio-Rad Publishes Corporate Sustainability Report for 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainability report for fiscal year ended December 31, 2022.
Jun 01, 2023 08:00 am ET
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and CFO Ilan Daskal.
May 08, 2023 08:00 am ET
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).
May 04, 2023 04:15 pm ET
Bio-Rad Reports First-Quarter 2023 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.
Apr 12, 2023 04:11 pm ET
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Feb 17, 2023 09:00 am ET
Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time).
Feb 16, 2023 04:05 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.
Feb 08, 2023 07:00 am ET
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.
Feb 07, 2023 09:00 am ET
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products...
Jan 06, 2023 09:00 am ET
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jan 04, 2023 09:00 am ET
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and COO Andrew Last, and Executive Vice President and CFO Ilan Daskal.
Oct 31, 2022 08:30 am ET
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a Fireside Chat event during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST).
Oct 27, 2022 04:05 pm ET
Bio-Rad Reports Third-Quarter 2022 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022.
Oct 17, 2022 08:30 am ET
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the third quarter of 2022 on Thursday, October 27, 2022, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Aug 03, 2022 04:15 pm ET
Bio-Rad Acquires Curiosity Diagnostics
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million, consisting of approximately $100 million in cash, and up to $70 million in future milestone payments.
Jul 28, 2022 04:17 pm ET
Bio-Rad Reports Second-Quarter 2022 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022.
Jul 18, 2022 04:15 pm ET
Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2022 on Thursday, July 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Jun 27, 2022 08:00 am ET
Bio-Rad Publishes Corporate Sustainability Report
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate sustainability report.
Apr 28, 2022 04:15 pm ET
Bio-Rad Reports First-Quarter 2022 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022.
Apr 18, 2022 08:00 am ET
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2022 on Thursday, April 28, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Mar 02, 2022 05:51 pm ET
Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering
The five year Notes bear interest at an annual rate of 3.300% and the ten year Notes bear interest at an annual rate of 3.700%. Bio-Rad intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures and investments in and acquisitions of other companies, products or technologies that it may identify in the future.
Feb 25, 2022 09:15 am ET
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad’s executive leadership team will provide an in-depth overview of the Company’s growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life Science Research and Clinical Diagnostics.
Feb 10, 2022 04:15 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021.
Feb 02, 2022 04:15 pm ET
Bio-Rad to Host Investor Day on February 25
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that it will host an in-person investor day in New York City on Friday, February 25, 2022, at 10:30 a.m. EST. A live webcast will also be available. Registration is required to attend the event.
Jan 25, 2022 08:00 am ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2021 on Thursday, February 10, 2022, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Jan 05, 2022 04:15 pm ET
Bio-Rad to Participate in Fireside Chat During the 40th Annual J.P. Morgan Healthcare Conference on January 11
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in a virtual Fireside Chat during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 PM (PST).
Dec 16, 2021 08:00 am ET
Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He succeeds Annette Tumolo who will retire from this role at that time. Dr. May will be responsible for providing leadership and management of the overall strategy and business direction for the company’s Life Science Group global operations.
Oct 28, 2021 04:15 pm ET
Bio-Rad Reports Third-Quarter 2021 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021.
Oct 15, 2021 08:00 am ET
Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2021 on Thursday, October 28, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Aug 31, 2021 08:00 am ET
Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that management will participate in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, at 11:40 AM (Pacific Time).
Jul 29, 2021 04:15 pm ET
Bio-Rad Reports Second-Quarter 2021 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021.
Jul 27, 2021 12:27 pm ET
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomics, Inc. (Nasdaq: TXG) have reached a final settlement to resolve multiple long-running litigations in Massachusetts, Delaware, California, Germany, and before the International Trade Commission.
Jul 27, 2021 06:30 am ET
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings...
Jul 14, 2021 04:15 pm ET
Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2021 on Thursday, July 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Jun 30, 2021 05:00 pm ET
Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.
Jun 21, 2021 08:00 am ET
Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective tool used to detect SARS-CoV-2 in a community’s wastewater.
May 20, 2021 08:30 am ET
Bio-Rad to Participate at Jefferies Virtual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO, will participate in a Fireside Chat at Jefferies Virtual Healthcare Conference on Wednesday, June 2, at noon (Pacific Time).
Apr 29, 2021 04:15 pm ET
Bio-Rad Reports First-Quarter 2021 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021.
Apr 15, 2021 08:30 am ET
Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2021 on Thursday, April 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Mar 05, 2021 04:16 pm ET
Bio-Rad to Participate in Barclays Global Healthcare Conference 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Barclays Global Healthcare Conference on Tuesday, March 9, at 10:15 AM (PST).
Feb 22, 2021 04:15 pm ET
Bio-Rad to Participate in Citi’s 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Wednesday, February 24, at 11:25 AM (PST).
Feb 11, 2021 04:20 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter ended December 31, 2020.
Jan 25, 2021 04:15 pm ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2020 on Thursday, February 11, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Jan 08, 2021 08:30 am ET
Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at 1:30 PM (PST).
Dec 10, 2020 05:33 pm ET
Bio-Rad Provides Outlook Through 2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the company’s commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measures.
Nov 13, 2020 08:31 am ET
Thinking about trading options or stock in Farfetch, Carnival Corp, General Electric, Tilray, or Bio-Rad Laboratories?
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FTCH, CCL, GE, TLRY, and BIO.
Oct 29, 2020 04:15 pm ET
Bio-Rad Reports Third-Quarter 2020 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020.
Oct 19, 2020 08:30 am ET
Bio-Rad to Report Third-Quarter 2020 Financial Results, Thursday, October 29, 2020
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2020 on Thursday, October 29, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Aug 04, 2020 08:30 am ET
The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld the lower Court’s finding on monetary damages amounting to $23.9 million at the time of the trial, November 2018, awarding Bio-Rad a 15 percent royalty on past and future sales, and a permanent injunction against 10x’s Single Cell 3’ Gen
Jul 30, 2020 04:15 pm ET
Bio-Rad Reports Second-Quarter 2020 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2020.
Jul 15, 2020 08:01 pm ET
Bio-Rad to Report Second-Quarter 2020 Financial Results, Thursday, July 30, 2020
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2020 on Thursday, July 30, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.
Jun 12, 2020 06:18 pm ET
S&P Dow Jones Indices Announces Tyler Technologies, Bio-Rad Laboratories and Teledyne Technologies Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, June 12, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, June 22 to coincide with the June quarterly rebalance.
May 06, 2020 04:15 pm ET
Bio-Rad Reports First-Quarter 2020 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2020.
May 04, 2020 07:27 pm ET
Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit
Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad’s QX200 and QXDx ddPCR systems.
Apr 30, 2020 04:51 pm ET
Bio-Rad’s SARS-CoV-2 (COVID-19) Serology Test Granted FDA Emergency Use Authorization, the First Total Antibody Test to Receive EUA from the FDA
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it was granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 Total Ab test, the first total antibody test receiving EUA from the FDA. Bio-Rad’s blood-based immunoassay test can help clinicians identify if an individual has developed antibodies against SARS-CoV-2, the virus associated with COVID-19 disease. The test has also met the CE mark requirements for Europe.
Apr 22, 2020 04:25 pm ET
Bio-Rad to Report First-Quarter 2020 Financial Results Wednesday, May 6, 2020
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2020 on Wednesday, May 6, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Apr 21, 2020 08:30 am ET
Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the commercial launch of its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease. Bio-Rad has applied for Emergency Use Authorization offered by the U.S. Food and Drug Administration and has met the CE mark requirements for Europe.
Apr 09, 2020 08:30 am ET
Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Terms of the acquisition were not disclosed. Bio-Rad will discuss the acquisition in more detail during its first-quarter 2020 financial results conference call.
Apr 07, 2020 08:30 am ET
Bio-Rad Announces the Launch of a Serology Assay to Detect Coronavirus (COVID-19) Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company is launching a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. Preliminary performance of the assay has been established and the kit is now undergoing clinical evaluation in several hospitals to further confirm clinical performance. Initial data collected on more than 700 samples has demonstrated specificity above 99 percent.
Mar 20, 2020 07:00 am ET
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE:BIO) (NYSE:BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S. Two studies published this month, ahead of peer review, reported that ddPCR testing showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR. Biodesix currently has
Mar 19, 2020 05:30 pm ET
New Studies Find Bio-Rad’s QX200 Droplet Digital PCR System Can Detect COVID-19 With Greater Sensitivity and Precision Than Other Existing Molecular Tests
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR (ddPCR) System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR.
Mar 18, 2020 07:24 pm ET
Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its Real-Time qPCR products are being used by testing laboratories globally to screen for COVID-19.
Mar 12, 2020 07:30 pm ET
Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that through its Exact Diagnostics product line Bio-Rad has launched a SARS CoV-2 Standard to support laboratory assay validation of coronavirus (COVID-19) testing. Bio-Rad is providing the SARS CoV-2 Standard to help labs validate their COVID-19 assay results and accelerate access to testing.
Feb 25, 2020 04:15 pm ET
Bio-Rad to Present at Barclays Global Healthcare Conference 2020 on March 10
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference 2020 on Tuesday, March 10, at 11:15 AM (EST), at the Loews Miami Beach Hotel, Florida.
Feb 13, 2020 06:23 pm ET
CORRECTING and REPLACING Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results
In the press release’s forward-looking statement, the second sentence should read: ...for the full year 2020 anticipating currency-neutral revenue growth of approximately 4.5 to 5.25 percent... (instead of ...for the full year 2020 anticipating currency-neutral revenue growth of approximately 4.5 to 5.0 percent...).
Feb 13, 2020 04:15 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2019.
Feb 03, 2020 09:37 pm ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2019 Financial Results Thursday, February 13, 2020
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2019 on Thursday, February 13, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jan 06, 2020 08:30 am ET
Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this role on December 31, 2019. Ms. Grantham Wright will be responsible for providing global leadership and management of the overall strategy and business direction for the company’s Clinical Diagnostics Group global operations.
Jan 02, 2020 04:15 pm ET
Bio-Rad to Participate at the 38th Annual J.P. Morgan Healthcare Conference on January 13
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 11 AM (Pacific Time), at the Westin St. Francis Hotel, San Francisco, California.
Dec 23, 2019 08:30 am ET
The International Trade Commission Issues Final Decision Affirming 10X Genomics Infringement of Three of Bio-Rad’s Patents
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the International Trade Commission (ITC) affirmed the Administrative Law Judge’s finding that 10X Genomics infringed three of Bio-Rad’s patents.
Dec 13, 2019 04:52 pm ET
Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) a global leader of life science research and clinical diagnostic products, today announced that the Company is making good progress recovering from a ransomware attack that was detected on Bio-Rad’s network on December 5, 2019. Once the malicious software was detected, Bio-Rad immediately took certain systems offline as part of its comprehensive response to contain the activity.
Oct 31, 2019 04:15 pm ET
Bio-Rad Reports Third-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019.
Oct 16, 2019 04:15 pm ET
Bio-Rad to Report Third-Quarter 2019 Financial Results Thursday, October 31, 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2019 on Thursday, October 31, 2019, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Sep 11, 2019 05:48 pm ET
Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has filed a patent infringement suit against 10X Genomics, Inc. in the United States District Court for the District of Delaware.
Aug 21, 2019 06:56 pm ET
Fitch Ratings Upgrades Bio-Rad to BBB, ‘Outlook Stable,’ Reflecting Continued Improvement in the Company’s Operating Performance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Fitch Ratings has upgraded Bio-Rad Laboratories, Inc.'s Long-Term Issuer-Default (IDR) to “BBB” from “BBB-.” The upgrade reflects Bio-Rad's improved EBITDA and FCF margins, which, according to Fitch Ratings, are trending toward industry averages as a result of cost rationalization initiatives and improvement of internal controls.
Aug 01, 2019 04:15 pm ET
Bio-Rad Reports Second-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2019.
Jul 24, 2019 09:52 pm ET
Delaware District Court Grants Bio-Rad’s Motion for Permanent Injunction Against 10X Genomics
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announces that today the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and pre- and post-judgement interest. The court also acknowledged Bio-Rad’s agreement to allow 10X to continue to sell consumables for use with already sold systems, subject to payment of a royalty.
Jul 23, 2019 08:46 pm ET
Bio-Rad to Report Second-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jun 27, 2019 07:34 pm ET
Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The outlook was changed to stable from positive. According to Moody’s, the upgrade reflects recent improvement in Bio-Rad’s operating performance including solid profit margin expansion as well as progress made in its multi-year ERP implementation. The upgrade also reflects the company’s consistently strong credit metri
Jun 03, 2019 02:03 pm ET
Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, at 10:40 AM (Pacific Time), at the Terranea Resort, Rancho Palos Verdes, California.
May 23, 2019 04:09 pm ET
Bio-Rad to Participate at Jefferies 2019 Global Healthcare Conference on June 4
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, at 10 AM (Eastern Time), in New York, NY.
May 08, 2019 04:15 pm ET
Bio-Rad Reports First Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.
Apr 23, 2019 04:15 pm ET
Bio-Rad to Participate in the Bank of America Merrill Lynch Health Care Conference 2019 in May
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 on May 14, at 10:40 AM Pacific Time, at the Encore Hotel, Las Vegas, Nevada.
Apr 22, 2019 05:00 pm ET
Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. In this role, Dr. Last is responsible for all operating functions of the company on a global basis.
Apr 15, 2019 07:03 pm ET
Bio-Rad to Report First-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Apr 08, 2019 04:15 pm ET
Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad’s IH-500, an automated random access system for blood typing and screening.
Apr 02, 2019 05:00 pm ET
Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019.
Apr 02, 2019 08:30 am ET
Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.
Mar 27, 2019 07:25 am ET
Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Transocean Ltd. (NYSE:RIG), Chipotle Mexican Grill, Inc. (NYSE:CMG),...
Mar 25, 2019 05:00 pm ET
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K")
Feb 28, 2019 04:38 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018.
Feb 14, 2019 07:28 pm ET
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Feb 12, 2019 06:31 pm ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2018 Financial Results Thursday, February 28, 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2018 on Thursday, February 28, 2019, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Feb 04, 2019 07:50 am ET
Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 20
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of T-Mobile US, Inc. (NASDAQ:TMUS), Noble Corporation (NYSE:NE), Akebia...
Jan 03, 2019 04:30 pm ET
Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A. Tsingos has informed the company of her intention to retire as Executive Vice President and Chief Financial Officer effective April 30, 2019. Ms. Tsingos will remain in her current role through April 30 and will assist in the orderly transition to a successor.
Jan 02, 2019 06:10 pm ET
Bio-Rad to Participate at the 37th Annual J.P. Morgan Healthcare Conference on January 8
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, at 1:30 PM (Pacific Time), at the Westin St. Francis Hotel, San Francisco, California.
Dec 03, 2018 08:30 am ET
Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments.
Nov 30, 2018 08:25 am ET
New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omeros Corporation (NASDAQ:OMER), Apple Inc. (NASDAQ:AAPL), Bio-Rad...
Nov 14, 2018 08:30 am ET
Bio-Rad and the University of Chicago Win Patent Infringement Case Against 10X Genomics Related to Droplet Microfluidics Technologies
A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products (NYSE: BIO and BIOb). In awarding Bio-Rad $23.9 million in damages, the jury unanimously found that all Single Cell and Linked-Read genomics products sold by 10X Genomics willfully infringed the patents owned by the University of Chicago and licensed to Bio-Rad.
Nov 13, 2018 08:30 am ET
Bio-Rad Wins USDA Contract for Its Pathogen Detection Testing Products
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the United States Department of Agriculture’s Food Safety and Inspection Service (USDA FSIS).
Nov 01, 2018 04:30 pm ET
Bio-Rad Reports Third-Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2018.
Oct 29, 2018 08:30 am ET
Bio-Rad Receives U.S. FDA Clearance for the IH-Reader 24, Expanding the Company’s Offering for the Blood Typing Market
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories.
Oct 23, 2018 07:20 am ET
Research Report Identifies Nordson, Willis Towers Watson Public, Bio-Rad Laboratories, Insperity, SAP SE, and Wesco Aircraft with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nordson Corporation (NASDAQ:NDSN), Willis Towers Watson Public Limited...
Oct 09, 2018 12:00 pm ET
Bio-Rad to Report Third-Quarter 2018 Financial Results Thursday, November 1, 2018
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2018 on Thursday, November 1, 2018, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Aug 29, 2018 07:27 pm ET
Bio-Rad to Participate at the Morgan Stanley 16th Annual Global Healthcare Conference on September 12
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday September 12, at 1:40 PM (ET), at The Grand Hyatt New York, New York City.
Aug 07, 2018 04:49 pm ET
Bio-Rad Reports Second-Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2018.
Jul 25, 2018 07:45 am ET
Report: Developing Opportunities within Acxiom, BofI Holding, On Assignment, Marriot Vacations Worldwide, Bio-Rad Laboratories, and Dime Community Bancshares — Future Expectations, Projections Moving
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acxiom Corporation (NASDAQ:ACXM), BofI Holding, Inc. (NASDAQ:BOFI), On...
Jul 16, 2018 01:49 pm ET
Bio-Rad to Report Second-Quarter 2018 Financial Results Tuesday, August 7, 2018
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2018 on Tuesday, August 7, 2018, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
May 30, 2018 08:02 pm ET
Bio-Rad to Present at Jefferies 2018 Global Healthcare Conference on June 5
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, at 10 AM (EST), in New York, NY.
May 18, 2018 08:00 am ET
Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals, PennyMac Financial Services, TeleTech, and Matrix Service with Renewed Outlook — Fundamental
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bio-Rad Laboratories, Inc. (NYSE:BIO), Bright Horizons Family Solutions...
May 08, 2018 04:25 pm ET
Bio-Rad Reports First Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2018.
Apr 18, 2018 04:24 pm ET
Bio-Rad to Report First-Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday, May 8, 2018, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Mar 23, 2018 08:30 am ET
Detailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CTS Corporation (NYSE:CTS), Lindblad Expeditions Holdings...
Mar 22, 2018 07:00 am ET
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the "2017 Form 10-K")
Mar 05, 2018 09:05 pm ET
Bio-Rad to Present at Barclays Global Healthcare Conference 2018 on March 14
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, at 3:50 PM (EST), at Loews Miami Beach Hotel, Florida.
Feb 27, 2018 04:22 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
Feb 27, 2018 01:30 pm ET
Bio-Rad Laboratories, Inc. Class A to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Bio-Rad Laboratories, Inc. Class A (NYSE: BIO) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 5:00 PM Eastern Time.
Feb 06, 2018 01:26 pm ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2017 Financial Results Tuesday, February 27, 2018
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2017 on Tuesday, February 27, 2018, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jan 24, 2018 08:10 am ET
Analysis: Positioning to Benefit within Oritani Financial, Bio-Rad Laboratories, Compass Diversified, Q2, Medpace, and Engility — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oritani Financial Corp. (NASDAQ:ORIT), Bio-Rad Laboratories,...
Jan 22, 2018 04:15 pm ET
Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents for manual blood typing methods.
Nov 28, 2017 09:00 am ET
Bio-Rad Authorizes New $250 Million Share Repurchase Program
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that its board of directors has authorized a new share repurchase program, granting the Company authority to repurchase, on a discretionary basis, up to $250 million of the outstanding shares of the Company’s common stock.
Nov 21, 2017 03:58 pm ET
Bio-Rad to Webcast Investor Day 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that it will webcast Bio-Rad Investor Day 2017 on November 28. The presentations and webcast will begin at 9 AM (ET).
Nov 02, 2017 04:15 pm ET
Bio-Rad Reports Third-Quarter 2017 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2017.
Oct 13, 2017 07:28 pm ET
Bio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2017 on Thursday, November 2, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Sep 28, 2017 12:47 pm ET
Senior Leadership of ARM, Verizon, Blizzard Entertainment, Peregrine Semiconductor, Extel Technologies and Bio-Rad Laboratories join EvoNexus Board of Directors
SAN DIEGO, Sept. 28, 2017 /PRNewswire/ -- Six technology industry leaders were elected on September 22nd to the Board of Directors of EvoNexus, further expanding the breadth of technology sectors that partner with the incubator.
Aug 03, 2017 04:41 pm ET
Bio-Rad Reports Second-Quarter 2017 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the second quarter ended June 30, 2017.
Jul 10, 2017 04:47 pm ET
Bio-Rad to Report Second-Quarter 2017 Financial Results Thursday, August 3, 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.b), a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2017 on Thursday, August 3, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jun 12, 2017 08:30 am ET
Bio-Rad Announces FDA Clearance of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis Testing Method
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection.
May 24, 2017 04:15 pm ET
Bio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient Results with the IH-1000 System
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for enhanced capability with its IH-Com data management software to manage patient results with the company's IH-1000 automated blood typing instrument.
May 04, 2017 04:15 pm ET
Bio-Rad Reports First-Quarter 2017 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2017.
Apr 10, 2017 01:21 pm ET
Bio-Rad to Report First-Quarter 2017 Financial Results Thursday, May 4, 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the first quarter 2017 on Thursday, May 4, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Mar 13, 2017 09:31 am ET
Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day
HERCULES, Calif., March 13, 2017 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced several significant strategic priorities, including initiating long term financial guidance, commitment to defining new capital allocation targets, and hosting an annual Investor Day later this year.
Mar 13, 2017 09:31 am ET
Bio-Rad Intends to Propose Three New Independent Directors
HERCULES, Calif., March 13, 2017 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that management intends to propose Jeffrey Edwards, Gregory Hinckley and Arnold Pinkston for election to its Board of Directors at the Company's 2017 Annual Meeting of Stockholders.
Feb 23, 2017 04:26 pm ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2016.
Jan 18, 2017 04:05 pm ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2016 Financial Results Thursday, February 23, 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2016 on Thursday, February 23, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Jan 18, 2017 03:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Rad Laboratories, Inc. - BIO
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company") (NYSE: BIO).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jan 16, 2017 08:30 am ET
Bio-Rad to Acquire RainDance Technologies and Droplet Intellectual Property
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017. The company will discuss the acquisition further during Bio-Rad's upcoming fourth-quarter and full-year 2016 financial results conference call.
Nov 01, 2016 04:15 pm ET
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2016.
Oct 24, 2016 08:30 am ET
Bio-Rad Introduces its IH-1000 Blood Typing System for the U.S. Market
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market. The system offers full automation and walk-away reliability, allowing laboratories to more efficiently manage their blood testing workload.
Oct 17, 2016 06:00 am ET
Globavir Announces Licensing Agreement with Bio-Rad for Globavir's Dengue Detection Technology
LOS ALTOS, Calif., Oct. 17, 2016 /PRNewswire/ -- Globavir Biosciences, Inc., a biotechnology company that develops therapeutics for infectious diseases and oncology, and diagnostics for infectious diseases, announced a partnership with Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products. Under the terms of the agreement, Bio-Rad will license Globavir's PanGlob™ dengue detection technology for use in an assay that includes dengue virus detection.  Financial terms of the agreement were not disclosed.
Oct 10, 2016 04:10 pm ET
Bio-Rad to Report Third-Quarter 2016 Financial Results Tuesday, November 1, 2016
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2016 on Tuesday, November 1, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Aug 03, 2016 04:15 pm ET
Bio-Rad Reports Second-Quarter 2016 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016.
Jul 11, 2016 02:02 pm ET
Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2016 on Wednesday, August 3, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day.
Jun 20, 2016 11:09 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, June 20, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
May 23, 2016 08:30 am ET
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
May 05, 2016 04:15 pm ET
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
Apr 13, 2016 05:30 pm ET
Bio-Rad to Report First-Quarter 2016 Financial Results Thursday, May 5, 2016
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb), a global provider of life science research and clinical diagnostic products, will report first-quarter financial results on Thursday, May 5, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.